trial · primary record
Alpha-1 15%
Alpha 1 Antitrypsin Deficiency
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2027-09-30 |
| Primary endpoint | Steady-state AUC of alpha1-PI over the weekly dosing interval (from 0 to 7 days) (AUC0-7 days) in the IV Treatment Period 1 and in the SC Treatment Period 2 for both dose levels |
| Registry ID | NCT07555483 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:37.933Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07555483
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.